Document is current
Any future updates will be listed below
-
Authors
Pivot, Xavier
Petit, Thierry
- License Information
-
More Information
Article History
Received: 4 April 2018
Revised: 13 June 2018
Accepted: 13 June 2018
First Online: 13 July 2018
Competing interests
: T.P. declares no conflict of interest. X.P. is the Principal Investigator for SB3 and HD201, which are trastuzumab biosimilars. X.P. has received honorariums for consulting by SamsungBioEpis.
Free to read: This content has been made available to all.
